A Recombinant Probiotic for Treatment and Prevention of Cholera

Gastroenterology

Volumn 130, Issue 6, 2006, Pages 1688-1695

  Focareta, Antonio ^a   Paton, James C ^a   Morona, Renato ^a   Cook, Jan ^a   Paton, Adrienne W ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA TOXIN; CWG 308; GANGLIOSIDE GM1; GLYCOSYLTRANSFERASE; LIPOPOLYSACCHARIDE; PROBIOTIC AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; CAMPYLOBACTER JEJUNI; CHOLERA; CONTROLLED STUDY; ESCHERICHIA COLI; GENE EXPRESSION; MOUSE; MOUSE STRAIN; NEISSERIA GONORRHOEAE; NONHUMAN; PRIORITY JOURNAL; VIBRIO CHOLERAE;

EID: 33646352688     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.02.005     Document Type: Article

References (28)

1. Karlsson K. Meaning and therapeutic potential of microbial recognition of host glycoconjugates. Mol Microbiol 19 (1998) 1-11
2. Paton A.W., Morona R., and Paton J.C. A new biological agent for treatment of Shiga toxigenic Escherichia coli infections and dysentery in humans. Nat Med 6 (2000) 65-70
3. Paton A.W., Jennings M.P., Morona R., Focareta A., Roddam L.F., and Paton J.C. Recombinant probiotics for treatment and prevention of travellers' diarrhea. Gastroenterology 128 (2005) 1219-1228
4. Sack D.A., Sack R.B., Nair G.B., and Siddique A.K. Cholera. Lancet 363 (2004) 223-233
5. Fan E., Merritt E.A., Verlinde C.L.M.J., and Hol W.G.J. AB(5) toxins. structures and inhibitor design. Curr Opin Struct Biol 10 (2000) 680-686
6. Heinrichs D.E., Yethon J.A., Amor P.A., and Whitfield C. The assembly system for the outer core portion of R1- and R4-type lipopolysaccharides of Escherichia coli. J Biol Chem 273 (1998) 29497-29505
7. Neoh S.H., and Rowley D. The antigens of Vibrio cholerae involved in the vibriocidal action of antibody and complement. J Infect Dis 121 (1970) 505-513
8. Jobling M.G., and Holmes R.K. Construction of vectors with the p15a replicon, kanamycin resistance, inducible lacZα and pUC18 or pUC19 multiple cloning sites. Nucleic Acids Res 18 (1990) 5315-5316
9. Vieira J., and Messing J. New pUC-derived cloning vectors with different selectable markers and DNA replication origins. Gene 100 (1991) 189-194
10. Paton A.W., Morona R., and Paton J.C. Neutralization of Shiga toxins Stx1, Stx2c and Stx2e by recombinant bacteria expressing mimics of globotriose and globotetraose. Infect Immun 69 (2001) 1967-1970
11. Maniatis T., Fritsch E.F., and Sambrook J. Molecular cloning. a laboratory manual (1982), Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
12. Morona R., Brown M.H., Yeadon J., Heuzenroeder M.W., and Manning P.A. Effect of lipopolysaccharide core synthesis mutations on the production of Vibrio cholerae O-antigen in Escherichia coli K-12. FEMS Microbiol Lett 66 (1991) 279-285
13. Tsai C.M., and Frasch C.E. A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. Anal Biochem 119 (1982) 115-119
14. Gilbert M., Karwaski M.F., Bernatchez S., Young N.M., Taboada E., Michniewicz J., et al. The genetic bases for the variation in the lipo-oligosaccharide of the mucosal pathogen, Campylobacter jejuni. Biosynthesis of sialylated ganglioside mimics in the core oligosaccharide. J Biol Chem 277 (2002) 327-337
15. 1-like lipo-oligosaccharide of Campylobacter jejuni. Mol Microbiol 37 (2000) 501-504
16. St. Michael F., Szymanski C.M., Li J., Chan K.H., Khieu N.H., Larocque S., et al. The structures of the lipooligosaccharide and capsule polysaccharide of Campylobacter jejuni genome sequenced strain NCTC 11168. Eur J Biochem 269 (2002) 5119-5136
17. Neoh S.H., and Rowley D. Protection of infant mice against cholera by antibodies to three antigens of Vibrio cholerae. J Infect Dis 126 (1972) 41-47
18. Klose K.E. The suckling mouse model of cholera. Trends Microbiol 8 (2000) 189-191
19. Arosio D., Vrasidas I., Valentini P., Liskamp R.M., Pieters R.J., and Bernardi A. Synthesis and cholera toxin binding properties of multivalent GM1 mimics. Org Biomol Chem 2 (2004) 2113-2124
20. Merritt E.A., Zhang Z., Pickens J.C., Ahn M., Hol W.G., and Fan E. Characterization and crystal structure of a high-affinity pentavalent receptor-binding inhibitor for cholera toxin and E coli heat-labile enterotoxin. J Am Chem Soc 124 (2002) 8818-8824
21. Angelichio M.J., Spector J., Waldor M.K., and Camilli A. Vibrio cholerae intestinal population dynamics in the suckling mouse model of infection. Infect Immun 67 (1999) 3733-3739
22. Hughes R. Campylobacter jejuni in Guillain-Barré syndrome. Lancet Neurol 3 (2004) 644
23. Willison H.J., and Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain 125 (2002) 2591-2625
24. Prendergast M.M., and Moran A.P. Lipopolysaccharides in the development of the Guillain-Barré syndrome and Miller Fisher syndrome forms of acute inflammatory peripheral neuropathies. J Endotoxin Res 6 (2000) 341-359
25. Nachamkin I., Liu J., Li M., Ung H., Moran A.P., Prendergast M.M., et al. Campylobacter jejuni from patients with Guillain-Barré syndrome preferentially expresses a GD(1a)-like epitope. Infect Immun 70 (2002) 5299-5303
26. 1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barré syndrome. Proc Natl Acad Sci U S A 101 (2004) 11404-11409
27. Prendergast M.M., Tribble D.R., Baqar S., Scott D.A., Ferris J.A., Walker R.I., et al. In vivo phase variation and serologic response to lipooligosaccharide of Campylobacter jejuni in experimental human infection. Infect Immun 72 (2004) 916-922
28. Paton J.C., Rogers T.J., Morona R., and Paton A.W. Oral administration of formalin-killed recombinant bacteria expressing a mimic of the Shiga toxin receptor protects mice from fatal challenge with Shiga toxigenic Escherichia coli. Infect Immun 69 (2001) 1389-1393